Universidade do Extremo Sul Catarinense, Departamento de Medicina, Criciúma, SC, Brasil.
Hospital São José, Criciúma, SC, Brasil.
Arq Gastroenterol. 2021 Jan-Mar;58(1):32-38. doi: 10.1590/S0004-2803.202100000-07.
Intravenous (IV) use of proton pump inhibitors (PPIs) is advised only in cases of suspected upper gastrointestinal bleeding (UGIB) or impossibility of receiving oral medication, although there has been a persistent practice of their inappropriate use in health institutions.
The purpose of our study was to measure the inappropriate use of IV PPIs in a high complexity hospital in Brazil and to estimate its costs.
Retrospective study of 333 patients who received IV omeprazole between July and December of 2018 in a high complexity hospital in Brazil.
IV omeprazole was found to be appropriately prescribed in only 23.4% patient reports. This medication was administered mainly in cases of suspected UGIB (19.1%) and stress ulcer prophylaxis in patients with high risk of UGIB unable to receive medication orally (18.7%). It was observed a statistically significant association between adequate prescription and stress ulcer prophylaxis in patients with high risk of UGIB unable to receive medication orally; patient nil per os with valid indication for PPIs usage; prescription by intensive care unit doctors; prescription by emergency room doctors; intensive care unit admission; evolution to death; sepsis; and traumatic brain injury (P<0.05). On the other hand, inadequate prescription had a statistically significant association with surgical ward prescription and non-evolution to death (P<0.05). The estimated cost of the vials prescribed inadequately was US$1696.
There was a high number of inappropriate IV omeprazole prescriptions in the studied hospital, entailing greater costs to the institution and unnecessary risks.
静脉注射质子泵抑制剂(PPIs)仅在疑似上消化道出血(UGIB)或无法口服给药的情况下建议使用,尽管医疗机构一直存在不合理使用 PPI 的情况。
本研究旨在测量巴西一家高复杂度医院中静脉注射 PPI 的不合理使用情况,并估计其成本。
对 2018 年 7 月至 12 月期间在巴西一家高复杂度医院接受静脉注射奥美拉唑的 333 名患者进行回顾性研究。
仅 23.4%的患者报告显示静脉注射奥美拉唑的处方是合理的。这种药物主要用于疑似 UGIB(19.1%)和应激性溃疡预防,用于不能口服给药的高危 UGIB 患者(18.7%)。我们观察到,在不能口服给药的高危 UGIB 患者中,适当的处方与应激性溃疡预防之间存在统计学显著关联;患者不能进食且有 PPI 使用指征;由重症监护病房医生开具处方;由急诊室医生开具处方;入住重症监护病房;进展至死亡;脓毒症;和创伤性脑损伤(P<0.05)。另一方面,不适当的处方与外科病房的处方和未进展至死亡之间存在统计学显著关联(P<0.05)。评估发现,开处方不合理的小瓶奥美拉唑的估计费用为 1696 美元。
在研究医院中,静脉注射奥美拉唑的不合理处方数量较多,这给机构带来了更高的成本和不必要的风险。